Aligos Therapeutics Appoints David Perry as Vice President of Business Development
Aligos Therapeutics (Nasdaq: ALGS) has appointed David Perry as Vice President of Business Development, effective immediately. Perry brings over 20 years of experience in the life sciences industry, with expertise in corporate strategy, business development, and investment management. His most recent role was Senior Director of Business Development at Sangamo Therapeutics, where he led a significant licensing deal with Genentech.
Prior to Sangamo, Perry served as Senior Director and Head of Business Development at Apexigen Inc., where he played a key role in the company's acquisition by Pyxis Oncology. Aligos' Executive VP and CFO, Lesley Ann Calhoun, expressed confidence that Perry's expertise in leading valuable partnerships will be important in maximizing the potential of Aligos' pipeline, including ALG-055009, which recently reported positive topline data.
Aligos Therapeutics (Nasdaq: ALGS) ha nominato David Perry Vice Presidente dello Sviluppo Commerciale, con effetto immediato. Perry porta con sé oltre 20 anni di esperienza nell'industria delle scienze della vita, con competenze nella strategia aziendale, nello sviluppo commerciale e nella gestione degli investimenti. Il suo ruolo più recente è stato Direttore Senior dello Sviluppo Commerciale presso Sangamo Therapeutics, dove ha guidato un importante accordo di licenza con Genentech.
Prima di Sangamo, Perry ha ricoperto il ruolo di Direttore Senior e Capo dello Sviluppo Commerciale presso Apexigen Inc., dove ha avuto un ruolo fondamentale nell'acquisizione dell'azienda da parte di Pyxis Oncology. L'Executive VP e CFO di Aligos, Lesley Ann Calhoun, ha espresso fiducia nel fatto che l'esperienza di Perry nella leadership di partnership preziose sarà importante per massimizzare il potenziale del pipeline di Aligos, incluso ALG-055009, che ha recentemente riportato dati positivi.
Aligos Therapeutics (Nasdaq: ALGS) ha designado a David Perry como Vicepresidente de Desarrollo Comercial, con efecto inmediato. Perry aporta más de 20 años de experiencia en la industria de las ciencias biológicas, con experiencia en estrategia corporativa, desarrollo comercial y gestión de inversiones. Su papel más reciente fue como Director Senior de Desarrollo Comercial en Sangamo Therapeutics, donde lideró un importante acuerdo de licencia con Genentech.
Antes de unirse a Sangamo, Perry fue Director Senior y Jefe de Desarrollo Comercial en Apexigen Inc., donde desempeñó un papel clave en la adquisición de la empresa por parte de Pyxis Oncology. La VP Ejecutiva y CFO de Aligos, Lesley Ann Calhoun, expresó confianza en que la experiencia de Perry en liderar asociaciones valiosas será importante para maximizar el potencial del pipeline de Aligos, incluido ALG-055009, que recientemente informó datos positivos.
알리고스 테라퓨틱스(Nasdaq: ALGS)는 데이비드 페리를 비즈니스 개발 부사장으로 임명하였습니다, 즉시 효력을 발생합니다. 페리는 생명 과학 산업에서 20년 이상의 경험을 갖추고 있으며, 기업 전략, 비즈니스 개발 및 투자 관리에 대한 전문성을 보유하고 있습니다. 그의 가장 최근 역할은 상가모 테라퓨틱스의 비즈니스 개발 수석 이사로서, 여기서 그는 제넨텍과의 중요한 라이센스 계약을 이끌었습니다.
상가모 이전에는 페리는 에이펙시젠에서 비즈니스 개발 수석 이사 및 책임자로 일하며, 파이시스 종양학에 의한 회사 인수에서 핵심 역할을 했습니다. 알리고스의 부사장兼 CFO인 레슬리 앤 칼혼은 페리가 소중한 파트너십을 이끌었던 경험이 알리고스의 파이프라인, 특히 최근 긍정적인 톱라인 데이터를 보고한 ALG-055009의 잠재력을 극대화하는 데 중요할 것이라고 확신했습니다.
Aligos Therapeutics (Nasdaq: ALGS) a nommé David Perry Vice-Président du Développement Commercial, avec effet immédiat. Perry apporte plus de 20 ans d'expérience dans l'industrie des sciences de la vie, avec une expertise en stratégie d'entreprise, développement commercial et gestion d'investissements. Son dernier rôle était celui de Directeur Senior du Développement Commercial chez Sangamo Therapeutics, où il a dirigé un important accord de licence avec Genentech.
Avant Sangamo, Perry a été Directeur Senior et Responsable du Développement Commercial chez Apexigen Inc., où il a joué un rôle clé dans l'acquisition de l'entreprise par Pyxis Oncology. Lesley Ann Calhoun, VP Exécutif et CFO d'Aligos, a exprimé sa confiance dans le fait que l'expertise de Perry dans la direction de partenariats précieux sera importante pour maximiser le potentiel de la pipeline d'Aligos, y compris ALG-055009, qui a récemment rapporté des données positives en termes de résultats.
Aligos Therapeutics (Nasdaq: ALGS) hat David Perry zum Vizepräsidenten für Geschäftsentwicklung ernannt, mit sofortiger Wirkung. Perry bringt über 20 Jahre Erfahrung in der Biowissenschaftsbranche mit, mit Fachkenntnissen in Unternehmensstrategie, Geschäftsentwicklung und Investmentmanagement. Seine letzte Position war Senior Director of Business Development bei Sangamo Therapeutics, wo er einen bedeutenden Lizenzvertrag mit Genentech leitete.
Vor Sangamo war Perry Senior Director und Leiter der Geschäftsentwicklung bei Apexigen Inc., wo er eine Schlüsselrolle bei der Übernahme des Unternehmens durch Pyxis Oncology spielte. Lesley Ann Calhoun, Executive VP und CFO von Aligos, äußerte Vertrauen, dass Perrys Expertise in der Führung wertvoller Partnerschaften wichtig sein wird, um das Potenzial von Aligos’ Pipeline, einschließlich ALG-055009, das kürzlich positive Topline-Daten reported hat, zu maximieren.
- Appointment of experienced executive David Perry as VP of Business Development
- Perry's track record includes leading significant licensing deals and strategic acquisitions
- Recent positive topline data for ALG-055009 pipeline candidate
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of David Perry as Vice President of Business Development, effective immediately.
“We are pleased to welcome David to the Aligos team during this exciting time for the company,” said Lesley Ann Calhoun, Executive Vice President and Chief Financial Officer at Aligos. “David’s expertise in leading valuable partnerships will be instrumental as we strategically look to maximize the potential of our best-in-class pipeline, including ALG-055009, which recently announced positive topline data.”
“I am excited to join Aligos at this critical time in the Company’s growth, given the significant potential of its clinical stage therapeutics,” stated David Perry, Vice President, Business Development at Aligos. “I look forward to working with the team to strategically advance our drug candidates for patients searching for a better outcome.”
Mr. Perry joins Aligos with more than 20 years of experience in the life sciences industry, leading corporate strategy, business development and execution, financings and investment management. Most recently, he served as Senior Director of Business Development at Sangamo Therapeutics, where he was responsible for the company’s business strategy and partnering initiatives concerning the company's genomic medicine platform technologies. He led a pivotal transaction that resulted in Sangamo’s most recent licensing deal with Genentech, the first transaction involving its blood brain barrier crossing AAV capsid delivery platform. Previously, Mr. Perry served as Senior Director and Head of Business Development at Apexigen Inc., a clinical-stage oncology therapeutics company. There he led collaboration and licensing deals as well as co-leading a strategic alternatives process that resulted in the acquisition by Pyxis Oncology.
His prior experiences include corporate development at Sumitomo Chemical where he led M&A for a North American subsidiary and the establishment of a corporate venturing unit that contributed to multiple early-stage investments. He started his career in healthcare investment banking at Asante Partners. Mr. Perry earned a B.S. in environmental engineering from Tufts University.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Aligos Therapeutics
Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inzioevoke.com
FAQ
Who is the new Vice President of Business Development at Aligos Therapeutics (ALGS)?
What is David Perry's background before joining Aligos Therapeutics (ALGS)?
What recent positive news did Aligos Therapeutics (ALGS) announce about its pipeline?
What significant deal did David Perry lead at Sangamo Therapeutics?
